Margaret Mooney
National Cancer Institute · 86 works · 32,583 citations · h-index 26
Top works
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network
- Recommendations for the assessment of progression in randomised cancer treatment trials
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
- Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
- Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301
- Insurance Status and the Use of Guideline Therapy in the Treatment of Selected Cancers
- Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
- Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program
- Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007
- Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
- Patterns of Care for Adjuvant Therapy in a Random Population-Based Sample of Patients Diagnosed with Colorectal Cancer
- Primary Extremity Sarcoma: What Is the Appropriate Follow-Up?
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
- Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences
- Effective follow-up strategies in soft tissue sarcoma
- Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma
- Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301)
- Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials